Why Choose Private Wegovy or Mounjaro Over NHS Routes?
Private Wegovy or Mounjaro: Skip the NHS Waiting Game
The NHS pathway for Wegovy or Mounjaro typically requires a GP referral to specialist weight management services, followed by a 6+ month waiting list and strict eligibility criteria. Many patients discover they don't meet the narrow NHS thresholds despite having legitimate clinical needs. Private prescription eliminates these barriers entirely—our registered clinicians can assess your suitability for either Wegovy or Mounjaro within 3 working days.
Through EverydayMeds' private service, you receive the same genuine medications available on the NHS, but without the administrative delays. Whether you prefer Wegovy's proven semaglutide mechanism or Mounjaro's innovative dual-action approach, both options remain accessible through our streamlined process. This isn't about bypassing clinical care—it's about accessing timely treatment from qualified UK prescribers.
Wegovy or Mounjaro Pricing: Transparent Private Prescription Costs
Private Wegovy treatment starts at £79.99 for the 0.25mg starter dose (after applying discount code FIRST40 for new customers). The full escalation schedule includes 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. Our Getting Started bundles, like the Intro Duo (0.25mg & 0.5mg) for £169.99, provide convenient multi-dose packages. Returning customers benefit from the DOSE25 discount code applied at checkout.
Mounjaro pricing follows a similar structure, though specific costs vary by dose strength. Both Wegovy or Mounjaro options include next-day cold-chain delivery and ongoing clinical support from our GPhC #9012878 registered pharmacy team. No hidden fees, no membership charges—just transparent pricing for prescription-only weight management treatment delivered to your door.
Clinical Evidence: Wegovy or Mounjaro Trial Results
In the landmark STEP trials, patients taking Wegovy alongside diet and exercise achieved an average of ~clinically studied weight loss at 68 weeks, compared to ~2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent efficacy across different patient populations, including those with type 2 diabetes. Weight management results may vary between individuals, and treatment should always be combined with lifestyle modifications.
Mounjaro's SURMOUNT trials showed the potential benefits of dual GIP/GLP-1 receptor activation, though direct head-to-head comparisons between Wegovy or Mounjaro aren't available due to different trial designs and populations. Both medications represent evidence-based approaches to weight management when prescribed appropriately by qualified clinicians.
How Wegovy or Mounjaro Work: Understanding the Mechanisms
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. It works by slowing gastric emptying, reducing appetite, and promoting satiety after smaller meals—essentially helping you feel satisfied with less food. Mounjaro takes a different approach with tirzepatide, targeting both GLP-1 and GIP receptors for dual metabolic benefits. Both Wegovy or Mounjaro options may help reduce food cravings by working on brain appetite centres, though individual responses can vary significantly.
Ordering Wegovy or Mounjaro: Simple Private Prescription Process
Our streamlined ordering process begins with a 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Qualified UK prescribers review your application within 3 working days (or 24 hours with express service) to determine suitability for either Wegovy or Mounjaro. Once approved, your prescription-only medicine ships via next-day delivery in temperature-controlled packaging. No GP appointments, no referral letters, no months of waiting—just professional clinical care delivered efficiently.
Storage and Practical Considerations for Wegovy or Mounjaro
Both Wegovy or Mounjaro require refrigerated storage at 2-8°C before first use, though Wegovy offers superior travel flexibility with 6 weeks of room temperature stability (below 30°C) compared to Mounjaro's 21-day limit. The pre-filled FlexTouch pens make weekly injections straightforward, with clear dose escalation schedules to minimise side effects. Wegovy follows a structured 16-week escalation from 0.25mg to the maintenance 2.4mg dose, while Mounjaro has its own titration protocol. Both treatments require commitment to reduced-calorie diets and increased physical activity for optimal results.
Private Wegovy or Mounjaro: Investment in Long-term Health
Private prescription represents more than convenience—it's an investment in timely healthcare access when NHS resources are stretched. Many patients find the cost of private Wegovy or Mounjaro treatment offset by improved quality of life, reduced obesity-related health risks, and faster progress towards weight management goals. Our clinical team provides ongoing support throughout your treatment journey, adjusting prescriptions based on your individual response.
The SELECT cardiovascular outcomes trial demonstrated that Wegovy may reduce major cardiovascular events by 20% in eligible patients, highlighting potential benefits beyond weight management. While such outcomes aren't assured, they underscore why prompt access to evidence-based treatments like Wegovy or Mounjaro can be valuable for long-term health planning.
Start Your Wegovy or Mounjaro Journey Today
Ready to begin treatment without NHS delays? Visit https://everydaymeds.co.uk/collections/wegovy to complete your clinical assessment and explore our full range of dosing options. New customers save with discount code FIRST40, while returning patients use DOSE25 at checkout. Both Wegovy or Mounjaro remain available through our registered pharmacy service, with expert clinical guidance to help you choose the most appropriate option. Don't let waiting lists delay your health goals—professional weight management support is just three clicks away.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
